Genocea Biosciences, Inc. (GNCA) Stock: Why It’s Headed For The Bottom

0

Genocea Biosciences, Inc. (GNCA) is working its way for to the bottom in the market in today’s trading session. The stock, focused on the biotech industry, is currently priced at $3.66 after a move down of -5.18% so far in today’s session. As it relates to biotechnology companies, there are quite a few aspects that have the ability to cause declines in the market. One of the most common is news. Here are the recent stories associated with GNCA:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-25-19 08:37AM Penny Stocks to Buy Using Technical Analysis for June 2019
Jun-24-19 01:58PM Need To Know: Genocea Biosciences, Inc. (NASDAQ:GNCA) Insiders Have Been Buying Shares
Jun-20-19 09:52AM Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?
Jun-18-19 04:04PM Genocea Announces Proposed Public Offering of Common Stock
Jun-03-19 12:47PM Genocea Biosciences Rallies 50% On ASCO Presentation

Nonetheless, when making an investing decision, prospective investors should focus on far more than news, this is especially the case in the speculative biotech sector. Here’s what’s happing when it comes to Genocea Biosciences, Inc..

The Performance That We’ve Seen From GNCA

While a single session decline, like the move that we’re seeing from Genocea Biosciences, Inc. may cause fear in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s always a good idea to dig into trends for a period longer than a single trading day. When it comes to GNCA, here are the movements that investors have seen:

  • Past 5 Trading Sessions – In the past five trading sessions, GNCA has generated a change in value in the amount of -3.94%.
  • Past 30 Days – The performance from Genocea Biosciences, Inc. over the past month has been -30.94%.
  • Quarterly – Over the last three months, the stock has generated a return that comes to -36.46%
  • Past Six Months – Throughout the past 6 months, we have seen a change that works out to -20.43% from the stock.
  • Year To Date – Since the close of last year GNCA has generated a return on investment of 59.52%.
  • Full Year – Finally, in the past full year, we’ve seen performance that comes to -45.21% from GNCA. Over this period, the stock has traded at a high of -67.55% and a low price of 63.39%.

Rations That Investors Should Consider

Digging into a few key ratios associated with a stock can give investors a look of how risky and/or potentially profitable a pick may be. Here are a few of the most important ratios to consider when looking at GNCA.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the stock is headed for declines. Across the sector, biotech stocks can have a higher short ratio. However, we also see quite a few short squeezes in the sector. Nonetheless, with regard to Genocea Biosciences, Inc., it’s short ratio comes to 0.59.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Basically, they measure whether or not a company can pay its debts as they mature based on quick assets or current assets. Because many biotech many companies rely on continued investor support, the current and quick ratios can seem upsetting. Nonetheless, several good picks in the biotechnology space do have great quick and current ratios. In terms of GNCA, the quick and current ratios come to 2.50 and 2.50 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets owned by the company. as it relates to Genocea Biosciences, Inc., the book to share value ratio is 0.44.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotech companies struggle to keep cash on hand. So, if you’re interested in a biotechnology stock, this is a very important ratio to consider. In the case of GNCA, the cash to share value ratio is 1.16.

What Analysts Say About Genocea Biosciences, Inc.

Although it’s never a good idea to unknowingly follow the thoughts of analysts, it is a good idea to use their thoughts when validating your own thoughts when it comes to making an investment decision in the biotechnology space. Below are the recent moves that we have seen from analysts as it relates to GNCA.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-08-19 Resumed Stifel Buy $13
Mar-01-19 Reiterated Needham Buy
Feb-06-18 Upgrade Needham Hold → Buy $3
Sep-27-17 Downgrade Needham Buy → Hold
Sep-26-17 Downgrade Stifel Buy → Hold $15 → $2.50

Big Money And Genocea Biosciences, Inc.

One thing I’ve come to understand in my short time on Earth is that smart money tends to follow big money players. In general, investors that are looking to play it relatively safe will follow moves made by institutional investors and insiders. With that said, what does the big money picture look like when it comes to GNCA? Here’s the scoop:

Institutions own 31.10% of the company. Institutional interest has moved by 25.83% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of GNCA shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 25.00M shares of Genocea Biosciences, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, GNCA has a float of 22.99M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to GNCA, the short percent of the float is 2.06%.

Earnings

What have ween seen from GNCA in terms of financial results?Here’s the data:

  • Analyst Expectations – At the moment, analysts are expecting that the company will come up with earnings per diluted share in the amount of -2.69, with -0.75 being announced in the earnings report for the current quarter. Although this is not based on earnings, since we are talking on the topic of analysts, the stock is presently rated a 1.70 on a scale from 1 to 5 where 1 is the poorest analyst rating and 5 is the best possible rating.
  • 5-Year Sales – In the last half decade, Genocea Biosciences, Inc. has announced a movement in sales volume that adds up to 0. Earnings in the past 5 years have generated a change of 23.70%.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings data, or Q/Q data as it is often explained in the world of humans, GNCA has generated a earnings change by 31.40%. The company has also experienced movement with regard to revenue that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I’m very dependent on humans. A human built me! Even though my developers made it possible for me to learn, it’s a lot simpler to do so when I receive human feedback. Below this content, you will find a comment section. If you’d like for me to look at other information, update the way I write something, comprehend something from an alternative angle, or you’re interested in telling me anything else, I’d like to know. Please leave a comment below. I’ll read that lesson and I will use it to evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here